References
- Mrowietz U, van de Kerkhof PC. Management of palmoplantar pustulosis: do we need to change? Br J Dermatol. 2011;164(5):1–4. doi: 10.1111/j.1365-2133.2011.10233.x.
- Brunasso AMG, Massone C. Recent advances in palmoplantar pustulosis. Fac Rev. 2021;10:62. doi: 10.12703/r/10-62.
- Misiak-Galazka M, Zozula J, Rudnicka L. Palmoplantar pustulosis: recent advances in etiopathogenesis and emerging treatments. Am J Clin Dermatol. 2020;21(3):355–370. doi: 10.1007/s40257-020-00503-5.
- Ma M, Lu S, Hou X, et al. Novel JAK-1 inhibitor upadacitinib as a possible treatment for refractory SAPHO syndrome: a case report. Int J Rheum Dis. 2023;26(11):2335–2337. doi: 10.1111/1756-185X.14774.
- Koga T, Sato T, Umeda M, et al. Successful treatment of palmoplantar pustulosis with rheumatoid arthritis, with tofacitinib: impact of this JAK inhibitor on T-cell differentiation. Clin Immunol. 2016;173:147–148. doi: 10.1016/j.clim.2016.10.003.
- Mohr J, Rahbar Kooybaran N, Schon MP, et al. Response of palmoplantar pustulosis to upadacitinib. J Dtsch Dermatol Ges. 2023;21(3):280–282. doi: 10.1111/ddg.14969.
- Coates LC, Soriano ER, Corp N, et al. Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465–479. doi: 10.1038/s41584-022-00798-0.
- Andersen YMF, Augustin M, Petersen J, et al. Characteristics and prevalence of plaque psoriasis in patients with palmoplantar pustulosis. Br J Dermatol. 2019;181(5):976–982. doi: 10.1111/bjd.17832.
- Trattner H, Bluml S, Steiner I, et al. Quality of life and comorbidities in palmoplantar pustulosis - a cross-sectional study on 102 patients. J Eur Acad Dermatol Venereol. 2017;31(10):1681–1685. doi: 10.1111/jdv.14187.
- Wang HM, Xu JM, Jin HZ. Characteristics and burdens of disease in patients from Beijing with generalized pustular psoriasis and palmoplantar pustulosis: multicenter retrospective cohort study using a regional database. Am J Clin Dermatol. 2023;24(6):991–1002. doi: 10.1007/s40257-023-00807-2.
- Furer V, Kishimoto M, Tsuji S, et al. The diagnosis and treatment of adult patients with SAPHO syndrome: controversies revealed in a multidisciplinary international survey of physicians. Rheumatol Ther. 2020;7(4):883–891. doi: 10.1007/s40744-020-00235-2.
- Hayem G. SAPHO syndrome. Rev Prat. 2004;54(15):1635–1636.
- Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68(5):1060–1071. doi: 10.1002/art.39573.
- McInnes IB, Anderson JK, Magrey M, et al. Trial of upadacitinib and adalimumab for psoriatic arthritis. N Engl J Med. 2021;384(13):1227–1239. doi: 10.1056/NEJMoa2022516.
- Burmester GR, Cohen SB, Winthrop KL, et al. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023;9(1):e002735. doi: 10.1136/rmdopen-2022-002735.
- McInnes IB, Kato K, Magrey M, et al. Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study. RMD Open. 2021;7(3):e001838. doi: 10.1136/rmdopen-2021-001838.